&nbsp;

dapProstateJuly18.html

Jul 2018

Guidelines and Advice

Safety Considerations for the Implementation of Subcutaneous Rituximab Formulation

Status: Current
Version: 1

Jun 2018

Regimen

DURV

Cancer Type:

Lung,

Non-Small Cell

Intent: Curative

Funding:

New Drug Funding Program

Durvalumab - Locally Advanced Unresectable Stage III Non-Small Cell Lung Cancer Following Concurrent Chemoradiation

Drugs Used:

durvalumab

Quick Link(s):

Regimen Monograph

Jun 2024

Regimen

DENO

Cancer Type:

Hematologic,

Multiple Myeloma

Intent: Palliative

Drugs Used:

denosumab (Unfunded)

Quick Link(s):

Regimen Monograph

Aug 2024

Document

Dr. Debra Bournes

Nov 2018

Guidelines and Advice

Self-Management in Cancer: Quality Standards

Status: Current
ID: N/A
Version: 1

Nov 2018

Self-Management in Cancer Toolkit

Document

ST-QBPUpdateTracker

Dec 2018

Regimen

DABRTRAM

Cancer Type:

Skin,

Melanoma

Intent: Adjuvant, Curative

Funding:

Exceptional Access Program

daBRAfenib - For the adjuvant treatment of resected Stage III cutaneous melanoma according to clinical criteria

Exceptional Access Program

trametinib - For the adjuvant treatment of resected Stage III cutaneous melanoma according to clinical criteria

Drugs Used:

daBRAFenib,

trametinib

Quick Link(s):

Regimen Monograph

Jun 2021

Document

Defining_Advanced_Practice_in_Radiation_Therapy_A_feasibility_assessment_of_a_new_healthcare_provider_role_in_Ontario

Mar 2019

Regimen

DARA(MNT)

Cancer Type:

Hematologic,

Multiple Myeloma

Intent: Palliative

Funding:

New Drug Funding Program

Daratumumab - In Combination with Bortezomib and Dexamethasone for Relapsed Multiple Myeloma

New Drug Funding Program

Daratumumab in Combination with a Bortezomib-Based Regimen for Newly Diagnosed Transplant Ineligible Multiple Myeloma

Drugs Used:

daratumumab

Quick Link(s):

Regimen Monograph

Sep 2022

Document